ArticleFrontiers in medicine2025
The relationship between the timing of lung surgery and postoperative pulmonary complications in patients after SARS-CoV-2 infection: a prospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with a positive test for SARS-CoV-2 prior to elective surgery early in the pandemic have an elevated risk of perioperative mortality and pulmonary complications. Post-SARS-CoV-2 infection, pulmonary sequelae persist beyond the acute stage, necessitating recovery periods spanning months or even longer. Our study aimed to explore the correlation between the timing of thoracoscopic lung surgery and postoperative pulmonary complications (PPCs) in patients with a history of SARS-CoV-2 infection. Methods: We conducted a prospective cohort study, enrolling patients scheduled for elective thoracoscopic partial lung resection. Participants were categorized into two groups based on the duration since their SARS-CoV-2 infection: 5-10 weeks and 11-16 weeks. A total of 68 patients were included, with 34 in each group. The information about SARS-CoV-2 infection were collected; IL-6 and TNF- Results: Compared with the 5-10-week group, in the 11-16-week group, the levels of IL-6 and TNF- Conclusion: Patients infected with SARS-CoV-2 who underwent thoracoscopic lung surgery within 5 to 10 weeks after infection had a higher risk of PPCs than those who had surgery at 11 to 16 weeks post-infection. Clinical trial registration: https://clinicaltrials.gov/, ChiCTR2300071539.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.